ARTICLE | Clinical News
Ariad preclinical data
June 27, 2011 7:00 AM UTC
In a mouse xenograft model of epidermal growth factor receptor ( EGFR)-driven NSCLC, oral AP26113 at doses of >=25 mg/kg led to >33% tumor regression. Data will be presented at the World Conference o...